Prescription patterns and adequacy of blood pressure control among adult hypertensive patients in Kenya; findings and implications

Expert Review of Clinical Pharmacology

Volumn 10, Issue 11, 2017, Pages 1263-1271

  Mbui, Jennifer M ^a   Oluka, Margaret N ^a   Guantai, Eric M ^a   Sinei, Kipruto A ^a   Achieng, Loice ^a   Baker, Amanj ^b   Jande, Mary ^c   Massele, Amos ^d   Godman, Brian ^b,e,f  

^a UNIVERSITY OF NAIROBI   (Kenya)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c CATHOLIC UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^d UNIVERSITY OF BOTSWANA   (Botswana)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

Author keywords

antihypertensive medicines; Hypertension; Kenya; prescribing patterns; treatment guidelines

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FUROSEMIDE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; LOSARTAN; METHYLDOPA; NIFEDIPINE; PROPRANOLOL; SPIRONOLACTONE; TELMISARTAN; THIAZIDE DIURETIC AGENT; ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; COMORBIDITY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; FEMALE; HUMAN; HYPERTENSION; KENYA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRACTICE GUIDELINE; PRESCRIPTION; PROTOCOL COMPLIANCE; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; AMBULATORY CARE; BLOOD PRESSURE; CLINICAL PRACTICE; COMBINATION DRUG THERAPY; DRUG EFFECTS; MIDDLE AGED; OUTPATIENT; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYPERTENSION; KENYA; MALE; MIDDLE AGED; OUTPATIENTS; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85029449063     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1080/17512433.2017.1371590     Document Type: Article

References (58)

1. Kayima J, Wanyenze RK, Katamba A, et al. Hypertension awareness, treatment and control in Africa: a systematic review. BMC Cardiovasc Disord. 2013;13:54.
2. Lloyd-Sherlock P, Beard J, Minicuci N, et al. Hypertension among older adults in low- and middle-income countries: prevalence, awareness and control. Int J Epidemiol. 2014;43(1):116–128.
3. Dzudie A, Kengne AP, Muna WF, et al. Prevalence, awareness, treatment and control of hypertension in a self-selected sub-Saharan African urban population: a cross-sectional study. BMJ Open. 2012;2(4):e001217.
4. Cois A, Day C., Obesity trends and risk factors in the South African adult population. BMC Obes. 2015;2:42.
5. Goverwa TP, Masuka N, Tshimanga M, et al. Uncontrolled hypertension among hypertensive patients on treatment in Lupane District, Zimbabwe, 2012. BMC Res Notes. 2014;7:703.
6. Nielsen JO, Shrestha AD, Neupane D, et al. Non-adherence to anti-hypertensive medication in low- and middle-income countries: a systematic review and meta-analysis of 92443 subjects. J Hum Hypertens. 2017;31(1):14–21.
7. Olack B, Wabwire-Mangen F, Smeeth L, et al. Risk factors of hypertension among adults aged 35-64 years living in an urban slum Nairobi, Kenya. BMC Public Health. 2015;15:1251.
8. Werner ME, van de Vijver S, Adhiambo M, et al. Results of a hypertension and diabetes treatment program in the slums of Nairobi: a retrospective cohort study. BMC Health Serv Res. 2015;15:512.
9. Mathenge W, Foster A, Kuper H. Urbanization, ethnicity and cardiovascular risk in a population in transition in Nakuru, Kenya: a population-based survey. BMC Public Health. 2010;10:569.
10. Irazola VE, Gutierrez L, Bloomfield G, et al. Hypertension prevalence, awareness, treatment, and control in selected LMIC communities: results from the NHLBI/UHG network of centers of excellence for chronic diseases. Global Heart. 2016;11(1):47–59.
11. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217–223.
12. WHO. A global brief on hypertension–silent killer, global public health crisis. World Health Day. 2013. [cited 2016 Dec 7]. Available from: http://apps.who.int/iris/bitstream/10665/79059/1/WHO_DCO_WHD_2013.2_eng.pdf?ua=1
13. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. Jama. 2003;289(19):2534–2544.
14. Van Spall HG, Shanbhag D, Gabizon I, et al. Effectiveness of implementation strategies in improving physician adherence to guideline recommendations in heart failure: a systematic review protocol. BMJ Open. 2016;6(3):e009364.
15. Boonstra E, Lindbaek M, Khulumani P, et al. Adherence to treatment guidelines in primary health care facilities in Botswana. Trop Med Int Health. 2002;7:178–186.
16. Francke AL, Smit MC, De Veer AJE, et al. Factors influencing the implementation of clinical guidelines for health care professionals: a systematic meta-review. BMC Med Inform Decis Mak. 2008;8:38.
17. Taba P, Rosenthal M, Habicht J, et al. Barriers and facilitators to the implementation of clinical practice guidelines: a cross-sectional survey among physicians in Estonia. BMC Health Serv Res. 2012;12:455.
18. Donnellan C, Sweetman S, Shelley E., Health professionals’ adherence to stroke clinical guidelines: a review of the literature. Health Policy (Amsterdam, Netherlands). 2013;111(3):245–263.
19. National High Blood Pressure Education P. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Bethesda (MD): National Heart, Lung, and Blood Institute (US); 2004.
20. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). Jama. 2014;311(5):507–520.
21. Ministry of Medical Services Kenya, Ministry of Public Health and Sanitation Kenya. Standard treatment guidelines for management and referral of common conditions at levels 4-6: Hospitals. 36–37. Available from: http://apps.who.int/medicinedocs/documents/s21000en/s21000en.pdf
22. Oti SO, van de Vijver S, Gomez GB, et al. Outcomes and costs of implementing a community-based intervention for hypertension in an urban slum in Kenya. Bull World Health Organ. 2016;94(7):501–509.
23. Mutua EM, Gitonga MM, Mbuthia B, et al. Level of blood pressure control among hypertensive patients on follow-up in a Regional Referral Hospital in Central Kenya. Pan Afr Med J. 2014;18:278.
24. Hendriks ME, Wit FWNM, Roos MTL, et al. Hypertension in Sub-Saharan Africa: cross-sectional surveys in four rural and urban communities. PLoS One. 2012;7(3):e32638.
25. Achieng L, Joshi M, Ogola EN, et al. Adequacy of blood pressure control and level of adherence with antihypertensive therapy. East Afr Med J. 2009;86(11):499–506.
26. AMPATH. Leading with care. Available from: http://www.ampathkenya.org/
27. Keny A, Wanyee S, Kwaro D, et al. Developing a national-level concept dictionary for EHR implementations in Kenya. Stud Health Technol Inform. 2015;216:780–784.
28. Subramanian S, Tangka F, Edwards P, et al. Developing and testing a cost data collection instrument for noncommunicable disease registry planning. Cancer Epidemiol. 2016;45(Suppl 1):S4–s12.
29. Were MC, Mamlin BW, Tierney WM, et al. Concept dictionary creation and maintenance under resource constraints: lessons from the AMPATH medical record system. In: AMIA annual symposium proceedings AMIA symposium. American Medical Informatics Association, Maryland, USA, 2007. p. 791–795.
30. Subramanian S, Kibachio J, Hoover S, et al. Research for Actionable Policies: implementation science priorities to scale up non–communicable disease interventions in Kenya. J Glob Health. 2017;7(1). Available from: http://jogh.org/documents/issue201701/jogh-07-010204.pdf
31. Novartis. Kenya first country to launch ‘Novartis Access’, expanding affordable treatment options against chronic diseases. 2015 Oct 15. Available from: https://www.novartis.com/news/media-releases/kenya-first-country-launch-novartis-access-expanding-affordable-treatment
32. Ogola E, Health Heart Africa–the Kenyan experience. Available from: http://www.pascar.org/uploads/files/HEALTHY_HEART_AFRICA_Elijah_Ogola.pdf
33. Republic of Kenya Ministry of Health. Kenya National Strategy for the prevention and control of non-communicable diseases 2015 to 2020. Available from: http://www.who.int/nmh/ncd-task-force/kenya-strategy-ncds-2015-2020.pdf
34. Cochran W., Sampling techniques. 3rd ed. 1977. John Wiley & Sons, Inc., New Jersey, USA. ISBN: 978-0-471-16240-7. Available from: http://eu.wiley.com/WileyCDA/WileyTitle/productCd-047116240X.html
35. Mwangi K, Prescription patterns in management of hypertension at Kenyatta National Hospital’s Medical Outpatient Clinic. Available from: http://uonlibrary.uonbi.ac.ke/content/prescription-patterns-management-hypertension-kenyatta-national-hospitals-medical-outpatie-1
36. Wright JT, Probstfield JL, Cushman WC, et al. ALLHAT findings revisited in the context of subsequent analyses, other trials and meta-analyses. Arch Intern Med. 2009;169(9):832–842.
37. Finks S, Ripley TL. Sorting it out: what JNC 8 is and what it is not. J Manage Care Special Pharm. 2015;21(2):110–112.
38. Stephan D, Gaertner S, Cordeanu EM. A critical appraisal of the guidelines from France, the UK, Europe and the USA for the management of hypertension in adults. Arch Cardiovasc Dis. 2015;108(8–9):453–459.
39. Joshi MD, Ogola E, Karari E, et al. Adequacy of blood pressure controland level of adherence with antihypertensive therapy. East Afr Med J.2009;86:499–506.
40. Mufunda E, Albin B, Hjelm K. Differences in health and illness beliefs in Zimbabwean men and women with diabetes. Open Nurs J. 2012;6:117–125.
41. Stearne MR, Palmer SL, Hammersley MS, et al.Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ (Clin Res Ed). 1998;317(7160):703–713.
42. Okonofua EC, Simpson KN, Jesri A, et al. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension. 2006;47(3):345–351.
43. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281–1357.
44. Vrijens B, Antoniou S, Burnier M, et al. Current situation of medication adherence in hypertension. Front Pharmacol. 2017;8:100.
45. Khurshid F, Aqil M, Alam MS, et al. Antihypertensive medication prescribing patterns in a university teaching hospital in south Delhi. IJPSR. 2012;3(7):2057–2063.
46. Weinehall L, Ohgren B, Persson M, et al. High remaining risk in poorly treated hypertension: the ‘rule of halves’ still exists. J Hypertens. 2002;20(10):2081–2088.
47. Fernandez-Arias M, Acuna-Villaorduna A, Miranda JJ, et al. Adherence to pharmacotherapy and medication-related beliefs in patients with hypertension in Lima, Peru. PLoS One. 2014;9(12):e112875.
48. Eaddy MT, Cook CL, O’Day K, et al. How patient cost-sharing trends affect adherence and outcomes: a literature review. Pharm Ther. 2012;37(1):45–55.
49. Sinnott SJ, Buckley C, O’Riordan D, et al. The effect of copayments for prescriptions on adherence to prescription medicines in publicly insured populations; a systematic review and meta-analysis. PLoS One. 2013;8(5):e64914.
50. Barron J, Wahl P, Fisher M, et al. Effect of prescription copayments on adherence and treatment failure with oral antidiabetic medications. Pharm Ther. 2008;33(9):532–553.
51. Barbui C, Conti V. Adherence to generic v. brand antidepressant treatment and the key role of health system factors. Epidemiol Psychiatr Sci. 2015;24(1):23–26.
52. Simoens S, Sinnaeve PR. Patient co-payment and adherence to statins: a review and case studies. Cardiovasc Drugs Ther. 2014;28(1):99–109.
53. Kibuule D, Mubita M, Naikaku E, et al. An analysis of policies for cotrimoxazole, amoxicillin and azithromycin use in Namibia’s public sector: findings and therapeutic implications. Int J Clin Pract. 2017;71(2): e12918.
54. Barrios V, Escobar C. Which thiazide to choose as add-on therapy for hypertension? Integr Blood Press Control. 2014;7:35–47.
55. Vongpatanasin W. Hydrochlorothiazide is not the most useful nor versatile thiazide diuretic. Curr Opin Cardiol. 2015;30(4):361–365.
56. Dhalla IA, Gomes T, Yao Z, et al. Chlorthalidone versus hydrochlorothiazide for the treatment of hypertension in older adults: a population-based cohort study. Ann Intern Med. 2013;158(6):447–455.
57. Yoon SS, Fryar CD, Carroll MD. Hypertension prevalence and control among adults: United States, 2011–2014. NCHS Data Brief. 2015;220:1–8. Available from: https://www.cdc.gov/nchs/products/databriefs/db220.htm
58. Sengul S, Akpolat T, Erdem Y, et al. Changes in hypertension prevalence, awareness, treatment, and control rates in Turkey from 2003 to 2012. J Hypertens. 2016;34(6):1208–1217.